Qu blister pain tincture for external use intravenous infusion combined with acyclovir treatment of Herpes Zoster.doc

 PAGE \* MERGEFORMAT 6 Qu blister pain tincture for external use intravenous infusion combined with acyclovir treatment of Herpes Zoster [Abstract] Objective To observe the cured foam joint pain tincture for external use intravenous acyclovir treatment of herpes zoster clinical efficacy. Methods 46 cases of patients with herpes zoster were randomly divided into two groups. Treatment group, 26 cases cured pain tincture I blister lesions Department, spray combination therapy with intravenous infusion of acyclovir; control group, 20 patients given topical 3% acyclovir ointment acyclovir combined with intravenous infusion of medication, observe the effects were compared. Results In the treatment group in the first 4 days after treatment, significantly the efficiency of 69.2% and total effective rate was 92.3%; the first 7 days, cure rates of 69.2% and total effective rate 96.1%. The control group, the first 4 days after treatment, significantly the efficiency of 30.0%, the total effective rate 60.0%; the first 7 days, cure rates of 40.0%, the total effective rate 70.0%, the two groups were significantly difference (P amp;lt;0.05). Conclusion Qu blister pain tincture for external use intravenous infusion combined with acyclovir treatment of herpes zoster good. [Keywords:] Qu blisters of Herpes Zoster Pain Tincture Clinical herpes zoster is more common in a viral skin disease, Chinese medicine called ‘wrapped around waist fire Dan’, commonly known as ‘spider sore’. The disease is caused by neural invasion by a virus, so patients often feel a clear neuralgia, especially the elderly, if not carried out timely and effective treatment of neuropathic pain can be severe sequelae left is very painful and lingering. Search for safe and effective analgesic, anti-viral treatment, hospital development and utilization of non prescription, in the laboratory for processing refined, made from cured blisters pain tincture, at 2006-08 ~ 12 clinical trial, will now report on the re